Kidney Cancer

Combo Immunotherapy May Change Treatment for Kidney Cancer

Combo Immunotherapy May Change Treatment for Kidney Cancer

Response rates of the combination therapy increasing from 20% to 40%.

Targeted Multigene Panel Testing Useful for Hereditary Kidney Cancer

Targeted Multigene Panel Testing Useful for Hereditary Kidney Cancer

The most commonly altered genes were folliculin and fumarate hydratase in 1.8% and 1.3%, respectively.

Video: New Drug Proves Effective For Renal Cell Cancer Patients

Video: New Drug Proves Effective For Renal Cell Cancer Patients

Nivolumab combined with ipilimumab revealed manageable safety, antitumor activity and favorable responses garnering potential long-term benefits.

Type of Long-term Response to Targeted mRCC Therapy Affects Outcomes

Type of Long-term Response to Targeted mRCC Therapy Affects Outcomes

By

Patients who have a complete response to 2 or more years of anti-VEGF treatment have the best progression-free and overall survival.

What Not to Eat After Nephrectomy

What Not to Eat After Nephrectomy

By

Both urologists and nephrologists provide follow-up and continuity of care to patients after cancer nephrectomy.

BMI, Belly Fat Suggest Obesity-Related Cancer Risk

BMI, Belly Fat Suggest Obesity-Related Cancer Risk

BMI and location of excess body fat on the body are good indicators of obesity-related cancer risk.

Renal, Bladder Cancer Linked to Physical Inactivity

Renal, Bladder Cancer Linked to Physical Inactivity

By

Renal and bladder cancer patients were, respectively, 77% and 73% more likely to report lifetime physical inactivity than controls without cancer.

AUA Releases Updated Renal Mass Guidelines

AUA Releases Updated Renal Mass Guidelines

By

The document spells out in greater detail the criteria for radical and partial nephrectomy and for placing patients on active surveillance.

Early CRP Response to mRCC Drugs Predicts Survival

Early CRP Response to mRCC Drugs Predicts Survival

By

Changes in C-reactive protein levels 4 weeks after starting sunitinib or sorafenib treatment are associated with overall and progression-free survival.

AS Safe for Cystic Renal Masses in Selected Patients

AS Safe for Cystic Renal Masses in Selected Patients

By

In a single-center study, 24% of patients crossed over to treatment and 95% of patients were alive after 5 years of follow-up.

RCC Patients May Benefit from Nivolumab After Disease Progression

RCC Patients May Benefit from Nivolumab After Disease Progression

By

Nivolumab treatment beyond disease progression results in reductions in tumor burden, study finds.

 Recurrence of Low-Risk RCC Uncommon After Surgery

Recurrence of Low-Risk RCC Uncommon After Surgery

By

In a study, the 5-year risk of recurrence was 4.8%, 18.1%, and 46.3% for patients with low-, intermediate-, and high-risk disease.

Kidney Cancer Survival Better Among Metformin Users

Kidney Cancer Survival Better Among Metformin Users

By

Patients who used the drug had a 38% lower risk of dying from kidney cancer than non-users, meta-analysis shows.

Obesity and Kidney Disease: Hidden Consequences of the Epidemic

Obesity and Kidney Disease: Hidden Consequences of the Epidemic

World Kidney Day 2017 promotes education on the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that makes preventive behaviors an affordable option.

Targeted Therapies for Advanced RCC Improve Real-World Survival

Targeted Therapies for Advanced RCC Improve Real-World Survival

By

Overall survival among patients receiving first-line targeted therapy for advanced renal cell carcinoma increased significantly from 2006 to 2012.

Kidney Cancer Linked to Obesity

Kidney Cancer Linked to Obesity

By

Study also finds associations between adiposity and 10 other cancers, particularly digestive and hormone-related malignancies.

Broad-spectrum Antibiotics May Reduce Survival in mRCC

Broad-spectrum Antibiotics May Reduce Survival in mRCC

The researchers found that patients treated with ABT had decreased progression-free survival compared with those not receiving ATB.

Biologics Combo Shows Promise As First-Line mRCC Therapy

Biologics Combo Shows Promise As First-Line mRCC Therapy

By

In a phase 2 trial, atezolizumab plus bevacizumab improved PFS versus sunitinib in patients with renal cell carcinoma expressing PD-L1.

Sunitinib Dose Escalation May Benefit mRCC Patients

Sunitinib Dose Escalation May Benefit mRCC Patients

By

Added progression-free survival and prolonged overall survival possible, according to investigators.

Kidney Cancer Brain Metastases Not On the Rise

Kidney Cancer Brain Metastases Not On the Rise

By

Researchers develop a model to predict which patients are more likely to harbor brain metastases at cancer diagnosis.

Single RCC Bone Metastasis Predicts Better Survival

Single RCC Bone Metastasis Predicts Better Survival

By

Bone surgery should be considered in patients with solitary bone metastasis and no concomitant visceral metastases, according to investigators.

Metabolic Profiles May Distinguish RCC From Benign Masses

Metabolic Profiles May Distinguish RCC From Benign Masses

By

In a pilot study, metabolomic analyses of serum and urine showed a high level of predictive ability.

Guidelines Issued for Managing Small Renal Masses

Guidelines Issued for Managing Small Renal Masses

All patients with an SRM should be considered for a biopsy when the results may alter management.

Benign Disease Found in 14% of PN Cases

Benign Disease Found in 14% of PN Cases

By

The most common types of benign pathology were oncocytoma, angiomyolipoma, and complex cysts.

Office-Based Renal Mass Biopsy Safe

Office-Based Renal Mass Biopsy Safe

By

In a study, only 3 of 108 patients experienced complications, all of which were minor and required no hospitalization or further intervention.

RCC Adjuvant Therapy: Calculating Value

RCC Adjuvant Therapy: Calculating Value

By

Adjuvant treatments for RCC must be prioritized by physicians because ultimately value is determined by how medicine is practiced.

Robotic Nephrectomy for Localized RCC On The Rise

Robotic Nephrectomy for Localized RCC On The Rise

By

In 2013, nearly one third of all minimally invasive radical nephrectomies were performed with robotic assistance.

Study: Older Age Should Not Preclude Partial Nephrectomy

Study: Older Age Should Not Preclude Partial Nephrectomy

By

Partial and radical nephrectomy were associated with similar cancer-specific and overall survival in elderly patients.

CB-839 Drug Promising for Clear Cell, Papillary Renal Cell Cancer

CB-839 Drug Promising for Clear Cell, Papillary Renal Cell Cancer

In the 15 patients in the study, the dual treatment controlled tumors in 93% of the patients, who had either clear cell or papillary renal cell cancer.

Age at Cancer Diagnosis Predicts Cardiac Risk

Age at Cancer Diagnosis Predicts Cardiac Risk

Cancer patients diagnosed in their teens had a more than 4-fold higher risk of death from cardiac disease than patients who didn't have cancer.

Sign Up for Free e-newsletters